Providence, RINCT04680377Now EnrollingIRB Ready

NSCLC, Stage III Clinical Trial in Providence, RI

Access cutting-edge nsclc, stage iii treatment through this clinical trial at a research site in Providence. Study-provided care at no cost to qualified participants.

Sponsored by Jun Zhang, MD, PhD

Quick Self-Assessment

See if you qualify for this Providence location

Preparing your pre-screening questions…

Expert Care in Providence

Access nsclc, stage iii specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related nsclc, stage iii treatment provided free

Apply for This Providence Location

Check if you qualify for this nsclc, stage iii clinical trial in Providence, RI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Providence

    Convenient for RI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Providence site if eligible
  4. 4Begin participation

About This NSCLC, Stage III Study in Providence

This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.

Sponsor: Jun Zhang, MD, PhD

Who Can Participate

Inclusion Criteria

Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
Participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
Life expectancy ≥12 weeks
Males and females age ≥ 18 years
Allowable type and amount of prior therapy: Participants must have received two or more cycles of platinum-based chemotherapy (containing etoposide, vinblastine, vinorelbine, a taxane \[paclitaxel or docetaxel\], or pemetrexed) concurrently with definitive radiation therapy (54-66 Gy)
Eastern Cooperative Oncology Group (ECOG) Performance Status = 0 or 1
Body weight \>30 kg (66.14 lbs)
Participants must have histologically- or cytologically-documented NSCLC who present with locally advanced, unresectable (Stage III) disease
Participants must have not progressed following definitive, platinum-based, concurrent chemoradiation therapy
Adequate organ function based on laboratory results
Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use an acceptable form of contraception for the duration of study participation, and for the time specified following completion of therapy

Exclusion Criteria

Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or if the participant is in the follow-up period of an interventional study
Participation in another clinical study with an investigational product during the last 4 weeks prior to enrollment on this study
Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment
Mixed small cell and non-small cell lung cancer histology
Participants who receive sequential chemoradiation therapy for locally advanced NSCLC
Participants with locally advanced NSCLC who have progressed whilst definitive platinum based, concurrent chemoradiation therapy
Receipt of any investigational drug within 4 weeks prior to the first dose of durvalumab; and in the case of monoclonal antibodies (not immunotherapy) 6 weeks prior to the first dose of durvalumab
Participants who have received prior anti-programmed death (PD)-1, anti- programmed death ligand (PD-L)1 or anti- cytotoxic T-lymphocyte-associated protein (CTLA)-4
Participants who have received prior immunotherapy
Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational product (IP). Note: Participants, if enrolled, should not receive live vaccine whilst receiving durvalumab and up to 30 days after the last dose of IP
Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab
Any unresolved toxicity CTCAE ≥ Grade 2 from the prior chemoradiation / anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
Any grade pneumonitis from prior chemoradiation therapy
Active infection
Recent major surgery within 28 days prior to the first dose of study therapy
Active or prior documented autoimmune or inflammatory disorders
History of primary immunodeficiency
History of another primary malignancy
History of allogenic organ transplantation/organ transplant that requires therapeutic immunosuppression
History of leptomeningeal carcinomatosis
Participants with active ventricular arrhythmia requiring medication
Uncontrolled intercurrent illness
Participants who have progressed following definitive, platinum-based, concurrent chemoradiation therapy
Known allergy or hypersensitivity to durvalumab or any of durvalumab's excipients
Psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Providence?

Yes, this clinical trial (NCT04680377) has an active research site in Providence, RI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

NSCLC, Stage III Treatment Options in Providence, RI

If you're searching for nsclc, stage iii treatment options in Providence, RI, this clinical trial (NCT04680377) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Providence research site is actively enrolling participants for this clinical trial. You'll receive care from experienced nsclc, stage iii specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all nsclc, stage iii clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Providence, RI

See all lung cancer clinical trials recruiting in Providence — not just this study.

Browse Lung Cancer Trials in Providence →

Browse More Trials by Condition

Lung Cancer TrialsSmall Cell Lung Cancer TrialsNon-Small Cell Lung Cancer TrialsAll Conditions →

Ready to Join in Providence?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Providence, RI